Image may be NSFW.
Clik here to view.
Clik here to view.
Craig-Hallum starts TearLab at buy
Craig-Hallum Capital has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with a “buy” rating and 12-month price target of $5, calling the company a “unique diagnostics opportunity with...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Roth ups TearLab price target to $7
Roth Capital Partners has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $7 from $5, saying market awareness of TearLab is on the rise and TearLab system placements are...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Response Biomedical charting turnaround story
The new management team of Response Biomedical (OTCBB:RPBIF; TSX:RBM), with the strong support of its controlling shareholder, OrbiMed Advisors, has adopted an aggressive plan to drive sales and...
View Article
More Pages to Explore .....
